Background

Western equine encephalitis virus (WEEV) belongs to the genus Alphavirus within the Togaviridae family. This virus is originated by recombination of a new world Eastern equine encephalitis virus (EEEV) and the old world Sindbis virus (SINV).\(^1,3\) WEEV has a positive-strand RNA genome consisting of about 11,700 nucleotides.\(^1,4\) WEEV, EEEV and the related Venezuelan equine encephalitis virus (VEEV) were first isolated in the 1930s.\(^2,3\) The enzootic transmission cycle of WEEV includes the vertebrate hosts, birds and mosquitoes.\(^9\) The main mosquito vector of WEEV is Culex tarsalis.\(^10\) These alphaviruses can spread to the human central nervous system (CNS), causing symptoms ranging from mild febrile reactions to life-threatening encephalitis. WEEV has been classified as a biological warfare agent by the US Centers for Disease Control and Prevention. No anti-WEEV drugs are currently commercially available. Neutralizing antibodies are useful for the pre- and post-exposure treatment of WEEV infections. In this study, two immune antibody gene libraries were constructed from two macaques immunized with inactivated WEEV. Four antibodies were selected from these libraries and recloned as scFv-Fc, with a human Fc part. These antibodies bound WEEV specifically in ELISA with little or no cross-reaction with other alphaviruses. They were further analyzed by immunohistochemistry. All binders were suitable for the intracellular detection of WEEV particles. Neutralizing activity was determined in vitro. Three of the four antibodies were found to be neutralizing; about 1 ng/mL of the best antibody (ToR69–3A2) neutralized 50% of 5 x 10^4 TCID50/mL. Due to its human-like nature with a germinility index of 89% (VH) and 91% (VL), the ToR69–3A2 antibody is a promising candidate for future passive vaccine development.

This study describes the development of the first neutralizing antibodies against Western equine encephalitis virus (WEEV), a member of the genus Alphavirus. WEEV is transmitted by mosquitoes and can spread to the human central nervous system, causing symptoms ranging from mild febrile reactions to life-threatening encephalitis. WEEV has been classified as a biological warfare agent by the US Centers for Disease Control and Prevention. No anti-WEEV drugs are currently commercially available. Neutralizing antibodies are useful for the pre- and post-exposure treatment of WEEV infections. In this study, two immune antibody gene libraries were constructed from two macaques immunized with inactivated WEEV. Four antibodies were selected from these libraries and recloned as scFv-Fc, with a human Fc part. These antibodies bound WEEV specifically in ELISA with little or no cross-reaction with other alphaviruses. They were further analyzed by immunohistochemistry. All binders were suitable for the intracellular detection of WEEV particles. Neutralizing activity was determined in vitro. Three of the four antibodies were found to be neutralizing; about 1 ng/mL of the best antibody (ToR69–3A2) neutralized 50% of 5 x 10^4 TCID50/mL. Due to its human-like nature with a germinility index of 89% (VH) and 91% (VL), the ToR69–3A2 antibody is a promising candidate for future passive vaccine development.
antibody fragments (scFv) have been generated from the murine IgGs I1D238,39 and 10B540 for diagnostic purposes. To our knowledge, no neutralizing human or murine anti-WEEV antibodies have been described to date. Non-human primates (NHP) antibody gene libraries and phage display are highly suitable tools for the generation of human-like antibodies for diagnostic and therapeutic purposes.41,42 Phage display has been successfully used for the generation of murine,43 human44,45 and human-like46 antibodies against VEEV. This study concerns the generation and characterization of the first human-like neutralizing antibodies against WEEV.

Results

Animal immunization

Two macaques were immunized with β-PL-inactivated WEEV. The first macaque was immunized twice with a commercial veterinary vaccine (Fluvac Innovator Triple EFT plus EHV, 3EEV) against VEEV, EEEV and WEEV, and then three-times with β-PL-inactivated WEEV, with a final boost 5.5 mo after the initial immunization (referred to as “macaque 1”). The second macaque was immunized with 3EEV and VEEV,46 then boosted once with WEEV 4 mo after the last VEEV immunization (referred to as “macaque 2”). The immunization scheme is given in Figure 1. Anti-WEEV antibody titers were evaluated by ELISA. The titration ELISA for “macaque 1” is shown in Figure 2. The titrator reached 1/40960 before the final boost with WEEV, and 1/10249 for the second macaque (data not shown). The immunization strategy for “macaque 1” yielded higher anti-WEEV titers than immunization strategy for “macaque 2” with a series of VEEV immunization followed by one WEEV boost.

Antibody phage display library construction

For library cloning, total RNA was isolated from bone marrow lymphocytes after the final boost and reverse-transcribed to generate cDNA. The genes encoding VH and VL (kappa) were cloned into the phagemid pHAL14.47 Library quality was controlled by colony PCR, which showed over 90% full size inserts in both libraries. The final libraries consisted of 1.3 × 10⁷ independent clones for the library derived from “macaque 1,” and 2.4 × 10⁷ independent clones for the second library “macaque 2.” Both libraries were packaged with Hyperphage48,49 and satisfactory antibody presentation on phage was confirmed by total phage SDS-PAGE followed by western-blot and anti-pIII immunostaining (data not shown).

Antibody selection and binder gene analysis

Antibody selection (panning) was performed on antibody-captured active WEEV material. Three rounds of panning were performed and 96 soluble scFv antibody clones from the “macaque 1” library (ToR68 antibodies), and 48 antibody clones from the “macaque 2” library (ToR69 antibodies), were produced and analyzed by antigen ELISA. Four binders were identified in the ToR68 panning, and 42 binders were identified in the ToR69 panning. DNA sequencing revealed four unique antibodies from the “macaque 1” library and two unique antibodies from the “macaque 2” library. Two of the six unique binders displayed no specific antigen binding in more stringent assays and were not evaluated further. The corresponding human germline sequences, according to IMGT (www.imgt.org), and the germinality indices of the four validated anti-WEEV antibodies are given in Table 1. For comparison, the corresponding human germline sequences, the murine germline sequences and the germinality index of the murine anti-WEEV scFv 10B540 are given.

Table 1. Antibodies selected against WEEV

| Antibody clone | Antibody gene library | VH | JD | Germinality index | VL | JD | Germinality index |
|---------------|-----------------------|----|----|------------------|----|----|------------------|
| ToR68–2C3     | macaque 1              | IGHV1–2*02 | IGHD3–9*01 | 83.5% | IGHJ5*02 | IGKV7–3*01 | 73.0% |
| ToR68–2E9     | macaque 1              | IGHV3–43*02 | IGHD6–13*01 | 87.9% | IGHJ5*02 | IGKV1–17*01 | 88.8% |
| ToR68–3G2     | macaque 1              | IGHV4–4*07 | IGHD2–21*02 | 93.4% | IGHJ4*02 | IGKV3D–15*01 | 86.5% |
| ToR69–3A2     | macaque 2              | IGHV3–15*08 | IGHD3–22*01 | 89.0% | IGHJ5*02 | IGKV1–13*02 | 91.0% |
| 10B5          | ref. 40                | IGHV1–46*01 | IGHD4–23*01 | 65.9% | IGHJ4*03 | IGKV1–37*01 | 68.5% |

The most similar human germline genes were identified by IMGT (www.imgt.org). The germinality index describes the similarity of the antibodies to the corresponding human germline genes identified by IMGT/V-Quest in terms of the percent identity of the VH or VL framework region.

For comparison, the corresponding human germline sequences, the murine germline sequences and the germinality index of the murine anti-WEEV scFv 10B540 are given.

The selected scFv were recloned into the mammalian expression vector pCMX2.5-hIgG1-Fc-XP50 to produce the bivalent IgG-like scFv-Fc format. Chinese hamster ovary (CHO) cell lines were established and antibodies were produced in a bioreactor, purified and biotinylated.
Binding characteristics

The scFv-Fc versions of the antibodies were analyzed by titration ELISA on active WEEV particles, with a Semliki forest virus (SFV) monoclonal antibody 12/2 used as a capture antibody and the scFv-Fc antibodies or SFV12/2 as detection antibodies (Fig. 3). ToR68–2E9 and ToR68–3G2 showed the most efficient antigen binding, while some background binding was seen for ToR68–2E9 and ToR68–2C3. The determined detection limit was about $6 \times 10^3$ TCID$_{50}$/mL when using ToR68–2E9.

ELISA on active Alphavirus particles was used to analyze cross-reactions. Alphaviruses were captured in the range of $4 \times 10^5 – 8 \times 10^6$ TCID$_{50}$/mL, depending on the individual virus preparation used, and detected with the anti-WEEV antibodies in the scFv-Fc format (Fig. 4). Due to the different capture antibodies, this assay did not allow a truly quantitative comparison of antigen binding. All four antibodies bound to WEEV. Three of the antibodies were specific for WEEV, but ToR69–3A2 also showed weak binding to the Chikungunya.

All antibodies allowed the detection of WEEV-infected Vero cells by immunohistochemistry (Fig. 5).

WEEV neutralization

Inhibition of WEEV infection of Vero cells by the antibodies was analyzed in vitro using the neutralizing peroxidase-linked antibody (NPLA) assay. $5 \times 10^4$ TCID$_{50}$/mL WEEV were incubated with a dilution series of the antibodies, and two hours later, $2 \times 10^4$ Vero cells were infected. The non-neutralizing mAb SFV12/2 was used as a control (Fig. 6). While ToR68–2C3 did not show neutralizing activity, ToR68–2E9 and ToR68–3G2 antibodies achieved half-maximal neutralization at about 1–10 μg/mL antibody. Very efficient neutralization was observed with ToR69–3A2 antibody where about 1 ng/mL antibody was sufficient for the half-maximal neutralization of $5 \times 10^4$ TCID$_{50}$/mL.

Discussion

WEEV belongs to the new world Alphavirus genus. This virus is transmitted by mosquitoes and can spread to the human CNS, causing symptoms ranging from mild febrile reactions to encephalitis.\(^2,4,16\)

The post-exposure treatment of WEEV infections using interferon α protects mice only in a short time window of 6 h with limited efficacy.\(^5\) While the protection of mice against WEEV by hyperimmune serum from rabbits has been reported,\(^53\) no neutralizing or protective murine, human or human-like anti-WEEV or anti-EEEV monoclonal antibodies have yet been developed.\(^54\) The situation is different for other Alphaviruses. For passive immunization, human\(^55\) and murine\(^56\) antibody candidates for further therapeutic development have been described for Chikungunya. A panel of neutralizing murine\(^26,57\)
humanized, human-like monoclonal antibodies from non-human primates and one human antibody have been described for VEEV.

The immune antibody phage display libraries employed here were derived from immunized NHP, a technology that has been successfully used for the generation of neutralizing antibodies against other potential biological warfare agents, such as VEEV, anthrax lethal factor, botulinum toxins and ricin. The results of this study confirm that this approach, combined with the conversion to IgG equivalent scFv-Fc antibodies, provides a robust and quick solution for the generation of potential passive vaccination candidates. These phage display immune libraries are an alternative to the use of naïve antibody phage display libraries for antibody generation for situations in which serum samples from patients are available or NHP immunization can be justified ethically.

The V-gene sequences of the four validated anti-WEEV NHP antibodies were very similar to the corresponding human V-genes. The germinality index (GI), a value proposed for the initial assessment of immunogenicity in patients, describes the degree of identity of the corresponding FRs to the most similar human germline FR sequences. The GI values of the four scFv ranged from 83.5% to 93.4% for VH and from 73% to 91% for VL. Notably, at 73%, the GI of the light chain of ToR68–3G2 is very low. VBASE2 identifies the germline gene humIGKV085 as the most identical human gene, a gene that has not yet been assigned to any human kappa subfamily. The GI for this VL would be 91%. All macaque antibodies showed a higher identity to their human counterparts as the murine antibody 10B5, with a GI of 65.9%, respectively 68.5%. For comparison, the mean GI values of 100 average functional human scFv immunizations, the second macaque was immunized first with 3EEV, followed by VEEV immunizations and a final WEEV boost. However, this strategy failed to deliver an antibody with strong cross reactivity to VEEV within the limited number of analyzed clones.

No treatment is currently available for the post-exposure treatment of WEEV infections. The neutralizing antibody ToR69–3A2 against WEEV is a potential candidate for further development into the first passive anti-WEEV vaccine. Its human-like character should minimize potential immunogenicity and thus side effects of the treatment.

Material and Methods

Ethics statement and animal care
All animal studies presented here were specifically approved by the Institut de Recherche Biomédicale des Armées ethics committee ("Comité d’éthique de l’Institut de Recherche Biomédicale du Service de Santé des Armées") under authorization no. 2008/03.0 and were performed in accordance with all relevant French laws and ethics guidelines, including, in particular (1) "partie réglementaire du livre II du code rural (titer I, chapitre IV, section 5, sous section 3: expérimentation sur l’animal)," (2) "décret 87-848 du 19-10/1987 relatif aux expériences pratiquées sur les animaux vertébrés modifié par le décret 2001/464 du 29/05/2001," (3) "arrêté du 29 octobre 1990 relatif aux conditions de l’expérimentation animale pour le Ministère de la Défense" and (4) "instruction 844/DEF/DCSSA/AST/VEt du 9 avril 1991 relative aux conditions de réalisation de l’expérimentation animale.

Animal care procedures complied with the regulations detailed in the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals.
of Laboratory Animals. Animals were kept at constant temperature (22 °C ± 2 °C) and relative humidity (50%), with 12 h of artificial lighting per day. They were housed in individual cages (6 per room) and each had a perch. Animals were fed twice daily, once with dried food and once with fresh fruits and vegetables, and water was provided with the food. Animal technicians observed food intake and general behavior during feeding, and were able to contact a veterinary surgeon if necessary. The veterinary surgeon performed systematic visits to each NHP-room twice weekly. Our environmental enrichment program for non-human primates is limited to games with animal care staff and access to approved toys. The well-being of the animals was monitored by the attending veterinary surgeon. Animals were anaesthetised by an intramuscular injection of 10 mg/kg ketamine (Imalgene®, Merial) before the collection of blood or bone marrow samples. Analgesics were subsequently administered in the form of a single intramuscular injection of 5 mg/kg flunixin (Finadyne®, Schering Plough), if animal technicians suspected that the animal was in pain on the days following an intervention, on the basis of observations of its behavior. No non-human primates were sacrificed during this work.

**Cell culture and virus production**

All the viruses used in this study are Alphavirus species constituting models of biowarfare agents and belong to the strain collection of the Armed Forces Scientific Institute for Protection Technologies—NBC Protection (WIS). The WEEV strain H160/99 and EEEV strain H178/99 used in this study were received from the National Collection of Pathogenic Viruses (NCPV), UK.

Alphaviruses were propagated in baby hamster kidney or Vero-B4 (African green monkey kidney) cells, at 37 °C, under an atmosphere containing 4% CO₂, in a biosafety 3 facility, according to standard procedures, as described elsewhere. The cell lines were obtained from the DSMZ-ACC 33 (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH).

All viruses were harvested from infected cell monolayers, when 50 to 75% of the cells in the monolayer presented evidence of a viral cytopathic effect (CPE). Virus titers were determined by the 50% tissue culture infective dose (TCID₅₀/mL) method, as described by Spearman and Kaerber, or by plaque purification.

**Alphavirus purification**

Viruses were purified from the supernatants of infected Vero cells by affinity chromatography on Matrex Cellufine Sulfate medium (Virus Recovery System, VRS; Chisso America Inc.) or by isopycnic density gradient centrifugation, as described below. Matrex Cellufine Sulfate medium (VRS) is a cellulose bead medium functionalized with a low concentration of sulfate esters, which operates like a cation-exchange resin and has a high affinity for enveloped viruses. It selectively adsorbs complete virus particles and virus coats, according to their charge. Briefly, 50 mL of resin was equilibrated with adsorption buffer (0.01 M phosphate buffer, pH 7.5). Up to 200 mL of virus-containing prefiltered cell culture supernatant was loaded onto the column, which was then was washed twice with 0.01 M phosphate buffer, pH 7.5. Virus particles were then eluted with 1 M NaCl.

Virus particles were purified in two steps. The first step involved ultracentrifugation on a sucrose cushion (20% sucrose), causing low levels of mechanical stress and making it possible
to concentrate and collect morphologically intact particles by centrifugation at 112,000 \times g for 2 to 3 h. The pellet was resuspended in 0.5 to 1 mL phosphate-buffered saline (PBS) and further purified by isopycnic density gradient centrifugation (20 to 60% sucrose) for 18 h at 217,500 \times g. The virus-containing fraction was collected and stored at –80 °C for further analysis.

**Alphavirus inactivation**

All viral antigens were inactivated by incubation with a final concentration of 0.2% β-propiolactone (β-PL, Sigma-Aldrich). Immediately before use, a 10% β-PL solution was prepared and 0.1 mL of this dilution was incubated with 5 mL of virus-containing cell culture supernatant (pH 8 to 8.5) for 1 h at 4 °C and 4 h at 37 °C, with constant stirring. After 2 and 4 h, the pH of the cell culture supernatant was checked and adjusted if necessary. For complete hydrolysis of the β-PL remaining after inactivation, the supernatant was stored at 4 °C for another 12 to 18 h. The sample was centrifuged for 30 min at 10,006 \times g, and viral inactivation was checked by inoculating Vero cells and monitoring for cytopathic effects (CPE) for three to five days.

**Animal immunization**

A male cynomolgus macaque (Macaca fascicularis) was immunized by intramuscular injection with 100 μL of the commercially available veterinary vaccine Flucvac Innovator Triple EFT plus EHV (Fort Dodge Animal Health). This broad-range vaccine (3EEV) is normally administered to horses to protect them from equine encephalitis caused by the EEE, WEE and VEE viruses. This vaccine also contains inactivated rhinovirus and influenza virus together with tetanus toxoid, to protect horses against equine rhinopneumonitis, influenza and tetanus. One month later, the animal was immunized a second time with this vaccine. The macaque then received an intramuscular injection of 100 μL of VRS-purified β-PL-inactivated WEEV this final boost resulted in high yields of antibody RNA for RT-PCR. The immune library was generated 10 d after WEEV immunization. After each immune boost, serum samples were collected, inactivated by incubation for 20 min at 56 °C and tested for WEEV-specific antibodies by ELISA. For this purpose, VRS-purified culture supernatants from WEEV-infected Vero cells or uninfected cells were immobilized on 96-well microtiter plates (MaxisorpTM, Nunc). For the determination of WEEV-specific antibody titers, serial dilutions of pre-immune serum and of the sera obtained after second, third and fourth immunizations were used. Specifically bound antibodies were detected by incubation with rabbit anti-monkey IgG conjugated to horseradish peroxidase (1:10,000, Sigma-Aldrich) for 30 min at room temperature. Staining was performed with 3–3’, 5–5’-tetramethylbenzidine (TMB, Serva) and the reaction stopped with 0.5 M sulfuric acid after 10 min. Absorbance was measured at 450 nm.

**Library construction and packaging**

The library construction was performed as previously described.62,64,72 In brief, macaque bone marrow lymphocytes were sampled, RNA was isolated and reverse-transcribed into cDNA. The coding regions for the variable regions VL and VH were amplified and PCR products were cloned into the pGemT vector (Promega) yielding two antibody gene sublibraries, one encoding heavy chains (Fd fragment) and the other kappa light chains. The pGemT cloned PCR products were reamplified with two macaque oligonucleotide primer sets to introduce restriction sites for two step library cloning. The VH PCR products were first cloned into pHAL14,47 with the VL PCR fragments inserted in a second cloning step. The library was packaged with hyperphage46,49 as previously described.71 The scFv presentation of the library on the surface of the phage was assessed by

---

**Figure 6.** Inhibition of WEEV infection by anti-WEEV scFv-Fc antibodies. Neutralization was analyzed in NPLa assays. Antibody dilution series were incubated with 5 × 10^4 TCID₅₀/mL before 2 × 10^5 Vero cells were infected. As controls, the non-neutralizing mAb SFV12/2 was used or the cells were not infected. The infection of cells was demonstrated by the specific immunostaining of viral antigens by incubation with the biotinylated mAb SFV 12/2 (1:5,000) followed by streptavidin-HRP conjugate (1:4,000).
Selection of anti-WEEV antibodies

The selection of recombinant antibodies was performed according to modifications. Panning was performed in 96-well microtiter plates (MaxiSorp, Nunc). The plates were coated with 3 μg/mL of the capture antibody MAB8742 (anti-WEE antibody, clone 2A2C.3, Merck Millipore) in PBS pH 7.4 by incubation overnight at 4 °C. Affinity-purified WEEV (100 μL) was then added to the wells and the plates were incubated for two hours. Non-specific binding was eliminated by incubating antigen-coated wells and wells for the preincubation of the library with affinity-purified supernatant from non-infected Vero cells overnight. The wells for panning and for preincubation were blocked by incubation with 2% (w/v) skim milk powder in PBST overnight at 4 °C. The VRS-purified MAB8742 (anti-WEE antibody, clone 2A2C.3, Merck Millipore) in PBS pH 7.474 by incubation overnight at 4 °C. The supernatant containing 1% skim milk, 1% bovine serum albumin (BSA), a nonspecific murine IgG D1–4G2–4-1575 and the mixture was incubated for 1 h. The supernatant, containing the depleted library, was incubated in the wells with the captured WEEV particles at room temperature for 2 h and the wells were then washed 10 times with PBST. The bound scFv phage particles were eluted with 200 μL trypsin solution (10 μg/mL trypsin in PBS) at 37 °C for 30 min. The supernatant containing eluted scFv phage particles was transferred to a new tube. Eluted scFv phage (10 μL) was used for titration, as previously described. E. coli XL1-Blue MRFF’ (Agilent; 20 mL of culture in the exponential growth phase; OD600 = 0.4 – 0.5) was infected with the remaining scFv phage, by incubation at 37 °C for 30 min, without shaking. The infected cells were harvested by centrifugation for 10 min at 3220 × g and the pellet was resuspended in 250 μL of 2xTY medium supplemented with 100 mM glucose and 100 μg/mL ampicillin (2xTY-GA), plated on a 15 cm 2xTY agar plate supplemented with 100 mM glucose and 100 μg/mL ampicillin and incubated overnight at 37 °C. The resulting colonies were harvested in 5 mL of 2xTY-GA. The harvested colony suspension (100 μL) was mixed with 30 mL of 2xTY-GA and cultured to an OD600 of 0.4 to 0.5 at 37 °C, with shaking at 250 rpm. The bacterial suspension (5 mL, ~2.5 × 109 bacteria) was infected with 5 × 1010 M13K07 helper phage (Agilent), incubated at 37 °C for 30 min without shaking, and then for 30 min with shaking at 250 rpm. Infected cells were harvested by centrifugation for 10 min at 3220 × g and the pellet was resuspended in 30 mL of 2xTY supplemented with 100 μg/mL ampicillin and 50 μg/mL kanamycin (2xTY-AK). Antibody phage were produced by incubation for 16 h at 30 °C, with shaking at 250 rpm. Cells were harvested by centrifugation for 10 min at 3220 × g. The supernatant containing the antibody phages (~1 × 1012 cfu/mL) were used directly, for the next round of panning, or were stored at 4 °C for a few days.

Identification of monoclonal scFv by ELISA

Monoclonal scFv were produced as previously described. Plates were coated with 3 μg/mL of the capture antibody MAB8742 (anti-WEE antibody, clone 2A2C.3, Merck Millipore) in PBS pH 7.4 by incubation overnight at 4 °C. The VRS-purified WEEV supernatant was then added and plates were blocked with 2%MPBST. For binder identification, supernatants containing monoclonal scFv were incubated in the antigen-coated plates for 1.5 h at room temperature and washed three times with PBST. Bound scFv were detected with the murine mAb Myc1–9E10, which recognizes the C-terminal c-myc tag, and a goat anti-mouse serum conjugated to horseradish peroxidase (HRP) (Sigma; 1:10,000). Visualization was performed with TMB substrate (BIORAD) and the staining reaction was stopped by adding 100 μL of 0.5 M sulfuric acid. Absorbance at 450 nm and scattered light at 620 nm were measured and the value obtained at 620 nm was subtracted from the value obtained at 450 nm, with a SUNRISE microtiter plate reader (Tecan).

DNA sequencing

Antibody V-genes were sequenced by GATC Inc. using the oligonucleotide primer MHLacZ-Pro_F (5’ ggctcgtatgttgtgtgg 3'). Bioinformatic analysis was performed using web based resources, including IMGT/V-Quest (www.imgt.org) and VBASE2 (www.vbase2.org).

Construction of stable eukaryotic CHO transfectants and production of scFv-Fc fusions

WEEV specific scFv gene fragments were subcloned from the immune library vector pHAL14 into the mammalian expression vector pCMX2.5-hlgG1-Fc30 using Neol and NotI restriction sites.

For the stable production of WEEV-specific scFv-Fc fusion proteins, CHO-K1 from the American Type Culture Collection, (ATCC, No. CCL61) were transfected, in the presence of 80 μL Polyfect® (Qiagen GmbH), with 2 to 5 μg of plasmid DNA. Stable clones were selected for resistance to the aminoglycoside antibiotic genitin (G418). CHO cells were cultured overnight, to 60% to 80% confluence, in 1000 mm2 petri dishes (Nunc) containing non-selective Dulbecco’s Modified Eagle’s Medium (DMEM/HAM’s F-12), a nutrient mixture supplemented with L-glutamine and sodium bicarbonate, 10% (v/v) fetal calf serum (FCS) and 1% (w/v) penicillin and 1% (w/v) streptomycin (PA), at 37 °C, under an atmosphere containing 4% CO2. DNA-lipid complex formation was supported by the prior incubation of plasmid DNA and Polyfect® in serum – and antibiotic-free medium for 10 min at room temperature before transfection. During lipid-DNA complex formation, the CHO-K1 cells were washed with PBS. Medium (7 mL) supplemented with FCS and penicillin/streptomycin was then added to the complex. The mixture was then immediately mixed with the washed cells by gently swirling. Cells were incubated with the transfection complex for 3 h. The medium was then removed and replaced with fresh non-selective DMEM/HAM’s F-12 medium containing 10% (v/v) FCS and 1% (w/v) penicillin/streptomycin before incubation of the plates overnight at 37 °C, under an atmosphere containing 4% CO2. The medium was changed again one day after transfection. The transfected cells were detached by treatment with trypsin and dispensed at a dilution of 1:50 or 1:100 in new petri dishes, on selective medium also containing 700 mg/mL G418. The medium was changed every three to four days and the first stable G418-resistant clones were observed about three weeks after transfection. Four and five weeks after transfection, single clones were isolated and cultured.
on 24-well plates (Nunc). As productivity varies between clones, the production of WEEV-specific scFv-Fc fusions was assessed in the supernatants of 24 clones, by ELISA, as described above. Two of the CHO-K1-clones with the highest antibody production levels were then cultured in suspension, in DMEM/HAM’s F-12 medium containing 10% (v/v) (FCS), 1% (v/v) penicillin/streptomycin and 700 mg/mL G418, in a miniPerm bioreactor (Sarstedt), at 37 °C, under an atmosphere containing 4% CO₂. The culture supernatant was harvested twice weekly and replaced with fresh medium. Recombinant fusion proteins were purified by immunoaffinity chromatography on goat anti-human (GAH) Sepharose.

**Biotinylation of mAbs and scFc-Fc fusions**

The mAb or scFc-Fv antibodies (1 to 2 mg) were dissolved in sodium bicarbonate buffer, pH 8.5, and incubated with an aliquot of the biotin N-hydroxysuccinimide ester (long arm, water-soluble; Vector laboratories) corresponding to 1/10 the weight of the protein to be labeled. The mixture was incubated for 2 h at room temperature. The reaction was stopped by the addition of 10 mg glycine and the unreacted biotin was removed by gel filtration with PD-10 desalting columns containing Sephadex G25 (GE Healthcare), in accordance with the manufacturer’s protocol.

**Crossreactivity ELISA**

Plates were coated with 3 μg/mL capture antibody SFV12/2 (anti-WEEV, anti – Sindbis virus, anti-SFV and Chikungunya virus), mAb Pix c/t 6/2 (anti-Pixuna virus) (Greiser-Wilke, unpublished) or mAb VEE WIS1 (anti-VEEV) in PBS 10⁵ TCID₅₀/mL), EEEV (6×TCID₅₀/mL), WEEV (8×10⁶ TCID₅₀/mL), SINV (8×10⁶ TCID₅₀/mL), SFV (2.5×10⁵ TCID₅₀/mL), Chikungunya virus (CHIKV, 7×10⁵ TCID₅₀/mL) and Pixuna virus (PIXV, 8×10⁵ TCID₅₀/mL). Vero cell culture material was used as a control. The captured antibodies with no neutralizing activity, such as mAb 8742 or ToR69–3A2, mAb SFV12/2 or mAb 8742 (anti-VEEV antibody clone 2A2C.3, Merck Millipore) as a positive control. One day post infection (pi), the infected cells were fixed by incubation with 3% formalin in PBS for 3 h at 4 °C. The fixed samples were then incubated with their cognate antibodies in either a 1:5,000 or 1:10,000 dilution in PBS-T (PBS plus 1% FCS plus 0.1% Tween 20) for 1 h in a humid chamber at 37 °C. The fixed cells were washed three times in PBS-T (PBS plus 0.01% Tween 20) and incubated for 30 min with streptavidin-horseradish peroxidase conjugate (PSA, GE Healthcare) diluted 1:6,000 in PBS-F. The cells were thoroughly washed and the infected cells were visualized under a microscope following incubation with the precipitating colorimetric peroxidase substrate TMB for 10 min. The staining reaction was stopped by rinsing the plates with Millipore-purified water.

**Neutralizing peroxidase linked antibody assay (NPLA)**

The NPLA assay for scFv-Fc fusions and complete IgG antibodies was performed by a modified version of the procedure described by Jensen. All assays were performed in 96-well microtiter plates, with Vero cells used as the host for infection. A dilution series (50 μL) of scFv-Fc fusions or mAbs were incubated with an equal volume of WEE virus strain 160/99, with a TCID₅₀/mL of 5×10⁴, for 2 h at 37 °C, in 96-well plates. Following this incubation, 100 μL of freshly trypsin-treated Vero cells, at a density of 2×10⁵ cells/mL, was mixed with the antibody virus mixture. As a positive control for infection, virus samples, not previously incubated with antibody, and virus samples previously incubated with WEEV-specific antibodies with no neutralizing activity, such as mAb 8742 or mAb SFV12/2, were used. Non-infected Vero cells were used as a negative control. Cell monolayers were fixed 20 to 24 h post infection, by incubation with 3% formalin in PBS for 2 h at 4 °C. The monolayers were washed with PBS-T, overlaid with 100 μL of a 1:5,000 dilution of the WEEV-specific biotinylated mAb SFV12/2 and incubated for 90 min at room temperature. Bound biotinylated mAbs were detected by incubation with streptavidin-HRP conjugate (GE Healthcare, 1:4,000) as described above. An Olympus CK2 inverted microscope (Olympus) was used for bright field microscopy.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Luzie Voß for excellent technical assistance.
50. Jäger V, Büsow K, Wagner A, Weber S, Hurs T, Frentzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013; 13:52; PMID: 23802841; http://dx.doi.org/10.1186/1472-6750-13-52

51. Greiter-Wilk I, Moenning V, Kaaden OR, Figueredo LT. Most alphaviruses share a conserved epitopic region on their nucleocapsid protein. J Gen Virol 1989; 70:743-8; PMID: 2471798; http://dx.doi.org/10.1099/vir.0.81925-0

52. Wu QJH, Barabé ND, Huang YM, Rayner GA, Christopher ME, Schmaltz FL. Pre – and post- exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha. Virology 2007; 369:206-13; PMID: 17761207; http://dx.doi.org/10.1016/j.virol.2007.07.024

53. Sabin AB. Quantitative studies on prophylactic effectiveness of Western equine encephalitis antisera in mice. Proc Soc Exp Biol Med 1951; 78:655-8; PMID: 14901184; http://dx.doi.org/10.3181/00379727-78-19172

54. Reichert E, Classe A, Bectery A, Larsen J. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur Bioterror 2005; 7:413-27; PMID: 20028250; http://dx.doi.org/10.1089/bbp.2009.0032

55. Warrer L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RTP, Berin-Maghit S, Ng LFP, Abastado J-P, Desprès P, et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011; 186:3258-64; PMID: 21278338; http://dx.doi.org/10.4049/jimmunol.1003139

56. Pelat T, Hurs M, Laffly E, Condemine F, Borel C, Vidal D, Lefranç M-P, Diel S, Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID: 17517846; http://dx.doi.org/10.1128/AAC.01528-06

57. Chabhoum S, Hurs M, Liu Y, Pelat T, Miltehr S, Helmsing S, Jones RG, Sesardic D, Thullier P. Selection of antibodies by phage display. Methods Mol Biol 2014; 1060:215-43; PMID: 24037844; http://dx.doi.org/10.1007/978-1-62703-586-6_12

58. Roehrig JT, Day JW, Kinney RM. Antigenic analysis of the surface glycoproteins of a Venezuelan encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 1982; 118:269-78; PMID: 6778209; http://dx.doi.org/10.1016/0042-6822(82)90346-4

59. Goodchild SA, O’Brien LM, Stevens J, Muller MR, Manning OJ, Logue CH, D’Elia RV, Phillpotts RJ, Perkins SD. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res 2011; 90:1-8; PMID: 21301838; http://dx.doi.org/10.1016/j.antiviral.2011.01.010

60. Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J Gen Virol 2006; 87:2467-76; PMID: 16894148; http://dx.doi.org/10.1099/vir.0.81925-0

61. O’Brien LM, Underwood-Fowler CD, Goodchild SA, Phelps AL, Phillpotts RJ. Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan encephalitis virus serum viruses. Virol J 2009; 6:206; PMID: 19925641; http://dx.doi.org/10.1186/1472-6757-6-206

62. Pelat T, Hurs M, Laffly E, Condemine F, Borel C, Vidal D, Lefranç M-P, Diel S, Thullier P. Isolation of a nanomolar scFv inhibiting the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID: 17517846; http://dx.doi.org/10.1128/AAC.01528-06

63. Chabhoum S, Hurs M, Liu Y, Pelat T, Miltehr S, Helmsing S, Jones RG, Sesardic D, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009; 9:60; PMID: 19563687; http://dx.doi.org/10.1186/1472-6757-9-60

64. Pelat T, Hurs M, Laffly E, Condemine F, Borel C, Vidal D, Lefranç M-P, Diel S, Thullier P. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 2009; 4:e6625; PMID: 19767567; http://dx.doi.org/10.1371/journal.pone.0006625

65. Pelat T, Hurs M, Liu Y, Pelat T, Miltehr S, Helmsing S, Jones RG, Sesardic D, Thullier P. Isolation of a nanomolar scFv inhibiting the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID: 17517846; http://dx.doi.org/10.1128/AAC.01528-06

66. Pelat T, Hurs M, Laffly E, Condemine F, Borel C, Vidal D, Lefranç M-P, Diel S, Thullier P. Isolation of a nanomolar scFv inhibiting the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID: 17517846; http://dx.doi.org/10.1128/AAC.01528-06

67. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranç M-P, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vivo and in silico engineering. J Mol Biol 2008; 384:1400-7; PMID: 18976662; http://dx.doi.org/10.1016/j.jmb.2008.10.033

68. USDA Animal Welfare Act (AWA). 7 U.S.C. 2131 et seq., as amended and Health Research Extension Act of 1985 (“Animals in Research”). 1985.

69. National Research Council. Guide for the Care and Use of Laboratory Animals. Eighth Edition. Washington: The National Academies Press; 2011.

70. Henchal EA, Gentry MK, McCown JM, Brandt WE. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982; 31:830-6; PMID: 6285749

71. Henchal EA, Gentry MK, McCown JM, Brandt WE. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 1982; 31:830-6; PMID: 6285749

72. Greiner-Wilk I, Moenning V, Kaaden OR, Slope RE. Detection of alphaviruses in a genus-specific antigen capture enzyme immunoassay using monoclonal antibodies. J Clin Microbiol 1991; 29:131-7; PMID: 1847149

73. Jensen MH. Detection of antibodies against hog cholera virus and bovine viral diarrheaa virus in porcine serum. A comparative examination using CF, PLA and NPLA assays. Acta Vet Scand 1981; 22:85-98; PMID: 6266240